AZ Receives European Commission’s OK for COPD Treatment

The European Commission has approved AstraZeneca’s Bevespi Aerosphere, a long-term chronic obstructive pulmonary disease (COPD) treatment that is administered via a pressurized metered-dose inhaler.

The twice daily, fixed-dose device combines glycopyrronium and formoterol fumarate.

AZ’s treatment is not indicated for the relief of acute bronchospasm or for treating asthma.